Related by context. All words. (Click for frequent words.) 71 prospectively defined 69 noninferiority 68 secondary efficacy endpoint 68 primary efficacy endpoint 67 achieved statistical significance 67 secondary endpoint 67 nonrandomized 66 secondary efficacy endpoints 66 composite endpoint 66 prespecified secondary 66 efficacy endpoint 66 evaluable 65 primary endpoint 64 postintervention 64 secondary endpoints 64 mg kg dose 64 Primary endpoints 64 nonfatal MI 64 endoscopic remission 64 periprocedural 63 efficacy endpoints 63 binary restenosis 63 timepoint 63 virologic failure 63 undetectable HBV DNA 63 definite stent thrombosis 62 Secondary endpoints included 62 Crohn Disease Activity 62 STRIDE PD 62 primary efficacy endpoints 62 reinfarction 62 viral kinetic 62 unfractionated heparin 62 primary endpoints 62 urinary N telopeptide 62 MMSE score 62 morphometric vertebral fractures 62 reach statistical significance 62 Secondary efficacy endpoints 62 subgroup analyzes 61 prognostic variables 61 baseline HbA1c 61 Secondary endpoints 61 CR nPR 61 HbA 1c 61 non inferiority 61 Secondary endpoints include 61 death reinfarction 61 mRCC 61 biochemical recurrence 61 nondiabetic patients 61 desvenlafaxine succinate 61 surrogate endpoint 61 IOP lowering 61 attain statistical significance 61 RE LY ® 61 posaconazole 61 statistically significant p = 61 β blockers 61 sirolimus eluting stents 61 CRp 61 intima media thickness 61 multivariate Cox 61 clinical endpoints 61 ALLHAT 61 dosing cohort 61 unblinded 61 dalteparin 61 progression TTP 61 CCyR 61 symptomatic VTE 60 unfractionated heparin UFH 60 NYHA functional class 60 epoetin alpha 60 insulin detemir 60 XIENCE V demonstrated 60 glycoprotein IIb IIIa inhibitors 60 PROTECT II 60 HbA1c levels 60 DLTs 60 HbA 1c levels 60 alteplase 60 TRITON TIMI 60 carotid IMT 60 MADIT II 60 ARB telmisartan 60 HOMA IR 60 teriflunomide 60 randomized blinded 60 everolimus eluting stents 60 dose escalation 60 HER2 expression 60 rFVIIa 60 SIMPADICO 60 Index CDAI 60 HCV RESPOND 2 60 CIMZIA TM 60 undetectable HCV RNA 60 Cmax 60 pCR 60 SVR# 60 DAPT 60 prospectively stratified 60 ACR# response 60 tumor progression TTP 60 CTEPH 60 mITT population 60 pharmacodynamic 60 univariate 60 LVEF 60 ipsilateral stroke 60 nonresponders 60 predefined criteria 60 residual stenosis 60 angiographic outcomes 60 pharmacodynamics PD 60 concomitant medications 59 viral kinetics 59 mg/m2 dose 59 subanalysis 59 Kaplan Meier estimate 59 OADs 59 MADRS score 59 pharmacokinetic parameters 59 p = NS 59 HCV SPRINT 59 randomized controlled trials RCTs 59 noninferior 59 NIHSS 59 leukocyte count 59 liver histology 59 pharmacodynamic endpoints 59 beta blocker therapy 59 angiographic restenosis 59 virological response 59 patients undergoing CABG 59 postprocedure 59 Pharmacokinetic parameters 59 NSABP C 59 genotypic resistance 59 serum phosphorous 59 coronary stenosis 59 demonstrated clinically meaningful 59 HAQ DI 59 postdose 59 Y BOCS 59 comparator arm 59 recurrent glioblastoma multiforme 59 Doxil ® 59 serum urate 59 eplerenone 59 eptifibatide 59 pharmacokinetics PK 59 LEXIVA r 59 Baseline characteristics 59 SCr 59 ATACAND 59 p = #.# [003] 59 HBeAg seroconversion 59 NATRECOR R 59 apolipoprotein B 59 haematologic 59 pharmacodynamic PD 59 thromboembolic 59 ximelagatran 59 irbesartan 59 sUA 59 Thrombolysis 59 thromboembolic events 59 SSRI citalopram 59 randomization 59 glycated hemoglobin levels 59 BENICAR HCT 59 pegylated interferon alfa 2b 59 active comparator 59 lispro 59 levosimendan 59 ADAS cog 59 atheroma volume 59 eculizumab therapy 59 ruboxistaurin 59 sustained virological response 59 nucleoside naive patients 59 F FDG PET 59 PASI scores 59 achieve statistical significance 59 RECIST Response Evaluation Criteria 59 statistical significance p 59 randomized multicenter trial 59 APTIVUS r 59 NovoTTF 59 certolizumab 59 elotuzumab 59 HbA1C levels 59 mcg albinterferon alfa 2b 59 posttreatment 59 Bonferroni correction 59 blinded randomized 59 coronary revascularization 59 CsA 58 tirofiban 58 metabolic parameters 58 complete cytogenetic 58 biochemical relapse 58 timepoints 58 otamixaban 58 #mg QD [001] 58 adenoma recurrence 58 pharmacokinetic PK 58 A1c levels 58 clinicopathological features 58 imatinib therapy 58 tolvaptan 58 microbiologically evaluable 58 HDRS 58 locoregional recurrence 58 insulin glargine 58 rt PA 58 fibrinolysis 58 antithrombotic therapy 58 thienopyridine 58 Kaplan Meier analysis 58 dose cohort 58 clazosentan 58 rolofylline 58 infarct size 58 ABC/3TC 58 relapsed MM 58 recurrent GBM 58 antidiabetic therapy 58 lymphadenectomy 58 complete cytogenetic response 58 NIHSS score 58 virologic response 58 n = 58 5-FU/LV 58 histologic 58 PRIMO CABG 58 hemoglobin A1c levels 58 dose regimens 58 AUA Symptom Score 58 RE LY trial 58 CDAI score 58 fibrinolytic therapy 58 trials RCTs 58 maximally tolerated dose 58 Teriflunomide 58 mITT 58 chlorambucil 58 HAM D# 58 clinically meaningful differences 58 plasma pharmacokinetics 58 mg TID 58 platelet reactivity 58 statistical significance 58 undergoing coronary angiography 58 nicardipine 58 ADAS Cog 58 NATRECOR ® 58 underwent resection 58 ancrod 58 virological failure 58 mg dose 58 intravesical therapy 58 μg kg 58 multicentre randomized 58 #mg/day [001] 58 androgen deprivation 58 randomized 58 postoperative mortality 58 RCTs 58 System IPSS 58 placebo p 58 QTc prolongation 58 EURIDIS 58 hemoglobin A1c HbA1c 58 PNH patients 58 idraparinux 58 free survival PFS 58 IV bisphosphonates 58 patients evaluable 58 lipid lowering therapy 58 Solid Tumors criteria 58 randomisation 58 diameter stenosis 58 HORIZONS AMI trial 58 aflibercept 58 peginterferon 58 invasive aspergillosis 58 sunitinib 58 cerebral vasospasm 58 univariate analysis 58 ACR# [002] 57 prospective multicenter randomized 57 adjuvant therapy 57 NPH insulin 57 GP IIb IIIa inhibitors 57 adefovir 57 sitaxsentan 57 hsCRP levels 57 antiplatelet therapy 57 NEVO ™ 57 mcg QD 57 ACUITY trial 57 DAS# CRP 57 intravenous dosing 57 decitabine 57 p = .# [002] 57 lopinavir r 57 MEND CABG II 57 SUVmax 57 QRS duration 57 serum phosphorus 57 multicenter randomized controlled 57 nonfatal myocardial infarction 57 SAEs 57 preoperative PSA 57 remission CR 57 methotrexate monotherapy 57 fosbretabulin 57 Kaplan Meier estimates 57 Lucentis monotherapy 57 colorectal liver metastases 57 TAXUS Express Stent 57 statistically significant p 57 ANOVA 57 clinically meaningful 57 nonsignificant 57 carotid intima media 57 MACCE 57 chemoradiotherapy 57 normotensive 57 XIENCE V PROMUS Stent 57 prospective randomized controlled 57 colorectal adenoma 57 pharmacodynamic effects 57 dose cohorts 57 neoadjuvant chemotherapy 57 lumbar spine BMD 57 posttransplant 57 KRAS mutations occur 57 placebo p = 57 CLARITY study 57 clevidipine 57 ribavirin RBV 57 covariate 57 thromboprophylaxis 57 serum HBV DNA 57 bosutinib 57 Montgomery Asberg Depression 57 lipid parameters 57 target vessel revascularization 57 alicaforsen enema 57 preintervention 57 RE LY 57 pramlintide metreleptin combination 57 NSTE ACS 57 QTcF 57 achieved ACR# 57 nab paclitaxel 57 TACE 57 HBeAg negative patients 57 percutaneous intervention 57 tecarfarin 57 -#.# log# 57 antipsychotic efficacy 57 intermittent dosing 57 xanthine oxidase inhibitor 57 adjuvant therapies 57 preoperative chemotherapy 57 Flu Cy 57 confirmed CCyR 57 ischemic cardiomyopathy 57 sipuleucel T 57 ACR Pedi 57 evaluable patients 57 Free Survival PFS 57 echocardiographic 57 Xelox 57 randomized multicenter 57 FOLFOX4 57 oblimersen 57 atazanavir ritonavir 57 Subgroup analyzes 57 mCRC patients 57 sirolimus 57 multivariate analyzes 57 PREZISTA r 57 metformin monotherapy 57 retrospective observational study 57 paclitaxel eluting stents 57 treatment emergent adverse 57 saline placebo 57 ascending doses 57 bivalirudin 57 segment binary restenosis 57 biopsy Gleason 57 CANCIDAS 57 administered subcutaneously 57 mg QD 57 clinicopathological 57 HAMD 57 thromboembolic complications 57 neurologic progression 57 multivariable Cox 57 caspofungin 57 pharmacologically relevant 57 LPV r 57 histological subtype 57 EDSS score 57 NEVO RES 57 exploratory endpoints 57 GPIIb IIIa inhibitors 57 efficacy evaluable 57 nonoperative treatment 57 detectable HCV RNA 57 histologic subtype 57 Montgomery Åsberg Depression 57 nonoperative 57 pain palliation 57 glargine 57 evaluable subjects 57 ejection fractions 57 ascending dose 57 QTc 57 phase Ib 57 debulking surgery 57 glycated hemoglobin HbA1c 57 GVAX 57 confirmatory clinical 57 oral rivaroxaban 57 SYNTAX trial 57 apremilast 57 oncologic outcomes 57 MoxDuo TM IR 57 PEGylated interferon beta 1a 57 clinically relevant 57 procalcitonin 57 Dose escalation 57 LVSD 57 serum calcium 57 Stage IIIb 57 myocardial ischemia 57 insulin lispro 57 histopathological 57 virologic 56 lanthanum carbonate 56 #mg/dL [002] 56 clopidogrel 56 clinically meaningful improvement 56 systolic dysfunction 56 KRAS status 56 plasma uric acid 56 postoperative AF 56 carotid artery stenting CAS 56 BCIRG 56 FOLPI 56 sustained virologic response 56 BENICAR 56 cerebrovascular events 56 metastatic HRPC 56 androgen suppression 56 achieved sustained virological 56 mcg kg 56 ICD implantation 56 prostate cancer PCa 56 acute coronary syndromes ACS 56 retrospective cohort 56 peginterferon alfa 2b 56 DAS# remission 56 recurrent VTE 56 antiretroviral naïve 56 systemic embolism 56 PRIMO CABG2 56 dose titration 56 prospective multicentre 56 cangrelor 56 TAXUS Stent 56 tapentadol ER 56 serum phosphate levels 56 ACCORD Lipid 56 multicenter randomized placebo controlled 56 Subgroup analysis 56 #mg BID [003] 56 liver metastases 56 acute STEMI 56 baseline LDH 56 conditional logistic regression 56 alanine aminotransferase ALT 56 stent binary restenosis 56 adalimumab 56 dose clopidogrel 56 alanine aminotransferase 56 cilostazol 56 underwent percutaneous coronary 56 IIIa inhibitor 56 FOLFIRI 56 CHAMPION PLATFORM 56 VAPRISOL 56 ADCS CGIC 56 macrovascular events 56 ROCKET AF 56 cytogenetic response 56 antiarrhythmic drug 56 IV NSCLC 56 FDA defined valvulopathy 56 TEAEs 56 serum IGF 56 phase IIIb 56 #mg QD [002] 56 antibody titer 56 coadministration 56 pretest probability 56 ABCB1 56 multicenter Phase II 56 recurrent DVT 56 gefitinib Iressa 56 HBeAg 56 fondaparinux 56 abacavir lamivudine 56 serum calcium levels 56 PCa 56 bovine thrombin 56 antihypertensive agents 56 fructosamine 56 IFN alfa 56 goserelin 56 intravesical 56 Octreolin 56 tenecteplase 56 pharmacokinetic equivalence 56 pharmacokinetic characteristics 56 reintervention 56 prostate carcinoma 56 prucalopride 56 ritonavir boosted lopinavir 56 lymphocyte count 56 intra arterial 56 angiographic follow 56 graft occlusion 56 postoperative complication 56 valvulopathy 56 perioperative mortality 56 fosamprenavir 56 Kaplan Meier curves 56 Phase Ib study 56 octreotide LAR 56 TIMP 1 56 Randomized clinical trials 56 IFN α 56 randomized #:#:# 56 kidney allograft 56 dosage regimens 56 PRADAXA #mg 56 eGFR 56 PANSS 56 RezularTM 56 direct thrombin inhibitors 56 ICD therapy 56 antihypertensive therapy 56 #mg/day [002] 56 PSADT 56 interobserver reliability 56 iniparib 56 Plicera 56 primary percutaneous coronary 56 PEG IFN 56 ADHD RS 56 PSA nadir 56 bolus injection 56 mcg BID 56 APPRAISE 56 Randomized Evaluation 56 cTnI 56 LV dysfunction 56 Brief Psychiatric 56 recurrent venous thromboembolism 56 nadroparin 56 deferoxamine 56 HbA1C 56 dosing cohorts 56 resectable 56 doxorubicin cyclophosphamide 56 Hb A1C 56 hematologic toxicity 56 1mg dose 56 ARCOXIA 56 antiarrhythmic drugs 56 Zevalin consolidation 56 LMWH 56 glycoprotein IIb IIIa inhibitor 56 prostatic adenocarcinoma 56 μmol L 56 NIH CPSI 56 bolus dose 56 romiplostim 56 oral anticoagulation 56 sirolimus stent 56 mcg mL 56 GSK# [001] 56 locoregional disease 56 P = .# 56 hypogonadal men 56 Neuropsychiatric Inventory NPI 56 myocardial infarction stroke 56 intact parathyroid hormone 56 EMPHASIS HF trial 56 electrophysiologic 56 response CCyR 56 antithrombotic 56 EMPHASIS HF 56 analgesic efficacy 56 biphasic insulin aspart 56 tumor histology 56 cisplatin vinorelbine 56 mg ustekinumab 56 glomerular filtration rate 56 subcutaneously administered 56 methacholine challenge 56 mL/min/#.# m 2 56 Fidaxomicin 56 repeat revascularization 56 pomalidomide 56 Meta analyzes 56 concurrent chemoradiation 56 mutated K ras 56 Response Evaluation Criteria 56 DMARD 56 placebo 56 flutamide 56 multivariable analysis 56 tertiles 56 retinal thickness 56 peg interferon 56 placebo controlled trials 56 % CI #.#-#.# [003] 56 -#.# ± [002] 56 CI -#.# 56 mCi kg 56 tumor recurrence 56 discontinuations 56 refractory AML 56 ACR# responses 56 completely resected 56 ACEI ARB 56 cediranib 56 oral antidiabetes 56 preclinical pharmacokinetic 56 angiotensin converting enzyme inhibitors 56 dacarbazine chemotherapy 56 aldosterone antagonists 56 salmeterol fluticasone 56 thromboembolism 56 plus dexamethasone 56 hyperoxaluria 56 protease inhibitor mutations 56 titrated glipizide 55 immunosuppressive regimen 55 hemodynamically significant 55 PREZISTA r arm 55 heavily pretreated 55 paroxysmal AF 55 splenectomized patients 55 NNT = 55 antiepileptics 55 isotype 55 CIMZIA ™ 55 QIDS SR 55 target lesion revascularizations 55 aspirin clopidogrel 55 cytoreductive nephrectomy 55 neoadjuvant 55 lipid lowering agents 55 endothelin receptor antagonists 55 Major Adverse Cardiac 55 intracoronary 55 preoperatively 55 #.#/#.# mmHg [001] 55 ticagrelor 55 QTc intervals 55 Folfox 55 post hoc 55 corticosteroid dose 55 enoximone 55 INCB# [003] 55 olmesartan 55 avosentan 55 HCV RNA 55 #ng/ml 55 Aflibercept 55 GnRH agonist 55 DSMB 55 glycated hemoglobin 55 elagolix 55 resected 55 d dimer 55 symptom exacerbation 55 hematological parameters 55 troponin T 55 tipranavir ritonavir 55 Omacetaxine mepesuccinate 55 elevated transaminases 55 YMRS 55 dose atorvastatin 55 R0 resection 55 revascularization 55 laboratory abnormalities 55 mg administered orally 55 Scale EDSS 55 Non inferiority 55 mRS 55 AEGR 55 logistic regression analysis 55 paricalcitol 55 glulisine 55 Carotid Revascularization Endarterectomy vs. 55 ug kg 55 MIST II 55 ACTEMRA TM 55 ZOLINZA 55 baseline A1C 55 revascularizations 55 multicenter randomized 55 pioglitazone 55 achieve sustained virologic 55 HF hospitalization 55 GAMMAGARD 55 g dL 55 TIMI 55 HMG CoA reductase inhibitors 55 mesalamine granules 55 R# #mg BID 55 dose proportionality 55 SYMMETRY trial 55 abciximab 55 evaluating REVLIMID 55 Timed Walk 55 BPH Symptom Score 55 #.#mg/dL 55 FOSRENOL ® 55 lipid lowering drugs 55 ACTIVE W 55 cardiovascular morbidity 55 bendamustine 55 monotherapy 55 pharmacodynamic markers 55 Elitek 55 macroalbuminuria 55 placebo controlled studies 55 MADRS 55 Aptivus ® 55 systemically administered 55 MADIT CRT trial 55 ischemia driven 55 cabazitaxel 55 prespecified criteria 55 #mg/m# [002] 55 GOUT 55 estimated GFR 55 FEV1 55 subcutaneous insulin 55 antiangiogenic therapy 55 Val HeFT 55 mg/m2 cohort 55 perioperative complications 55 placebo fluoxetine 55 anthracycline containing 55 surrogate markers 55 Rating Scale MADRS 55 clinical pharmacology studies 55 T#I [002] 55 serum uric acid 55 serum urate levels 55 MEND CABG 55 apoB 55 dipyridamole plus 55 placebo controlled 55 Unified Parkinson Disease 55 metastatic GIST 55 Insulin PH# 55 Solid Tumors RECIST 55 CHAMPION PCI 55 hematopoietic cancers 55 tasocitinib 55 revascularization procedures 55 dyssynchrony 55 clinico pathological 55 doxorubicin docetaxel 55 Ceplene/IL-2 55 azacitidine 55 ipsilateral breast 55 tranylcypromine 55 glatiramer acetate 55 serum concentrations 55 TLUS 55 MERLIN TIMI 55 p = #.# [002] 55 BoNTA 55 clodronate 55 prospective observational studies 55 pericardial effusion 55 ETDRS 55 assessing T DM1 55 antiplatelet drugs 55 IMPACT DCM 55 statistically significant 55 periprocedural MI 55 hemoglobin Hb 55 postoperative radiotherapy 55 lactate dehydrogenase LDH 55 cystectomy 55 demonstrated statistically significant 55 bezafibrate 55 CHADS2 55 reperfusion 55 corrected QT interval 55 dose cytarabine 55 recurrent ischemia 55 left ventricular LV 55 prostate cancer CaP 55 serum aminotransferase levels 55 hypofractionated 55 CALGB 55 glycemia 55 postop 55 limiting toxicity 55 oral olanzapine 55 ADAGIO study 55 RECIST 55 antithymocyte globulin 55 infliximab 55 vidofludimus 55 confidence interval CI 55 cranial irradiation 55 parathyroidectomy 55 polyp recurrence 55 OGTT 55 myocardial infarction MI 55 everolimus eluting stent 55 velafermin 55 symptomatic carotid stenosis 55 prospective multicenter 55 SCD HeFT 55 intratumoral 55 sorafenib Nexavar 55 NLX P# 55 nonmetastatic 55 HSCT 55 stenoses 55 hemorrhagic complications 55 aspartate aminotransferase AST 55 canakinumab 55 μg dose 55 specified secondary endpoints 55 fluvastatin 55 ARIXTRA 55 HIV RNA 55 carotid endarterectomy CEA 55 rHuEPO 55 oocytes retrieved 55 inhaled anticholinergics 55 SGRQ 55 follicular NHL 55 micafungin 55 adjuvant tamoxifen 55 riociguat 55 TAXUS V 55 GFT# 55 target lesion revascularization 55 amlodipine 55 multicenter trials 55 tipranavir r 55 antithrombotic agents 55 #mg BID [002] 55 enoxaparin 55 ziprasidone 55 insulin degludec 55 PEG Intron ® 55 TNF inhibitor 55 primary patency 55 VT VF 55 Tasigna prolongs 55 CCX# 55 4mg/kg 55 confidence intervals CIs 55 TDF FTC 55 serologically active patients 55 carboplatin paclitaxel 55 blind placebo 55 histologically confirmed 55 T2DM 55 galiximab 55 oral prednisolone 55 Kaplan Meier 55 oxycodone CR 55 phase IIb clinical 55 randomized controlled clinical trials 55 abacavir Ziagen 55 median PFS 55 methotrexate therapy 55 fluoropyrimidine 55 BARI 2D 55 Negative Syndrome 55 plasma renin activity 55 undergoing CABG 55 Kaplan Meier survival 55 hepatocellular carcinomas 55 TNF antagonist 55 metastatic malignant melanoma 55 NCEP ATP III 55 oral diclofenac 55 NYHA class 55 biliary tract cancer 55 neoadjuvant therapy 55 HIV HCV coinfected 55 gemcitabine Gemzar 55 RAPAFLO R 55 clinically evaluable 55 mTOR inhibitors 55 mg BID 55 ketorolac 55 pharmacodynamic parameters 54 Lp PLA 2 54 PCWP 54 Sustained virologic response 54 CARE HF 54 mg d 54 Enoxaparin 54 posttest 54 FOLFOX 54 aminotransferase levels 54 LOVENOX 54 BEXXAR Therapeutic Regimen 54 dose dose escalation 54 prospective multicenter study 54 spontaneous bowel movements 54 specified primary endpoint 54 #mg BID [001] 54 CIMZIA TM certolizumab pegol 54 Taxus Stent 54 prospectively randomized 54 Complication rates 54 pretransplant 54 CTCAE 54 statistically significant differences 54 TURBT 54 AVERROES 54 Myocardial Infarction Study 54 postmenopausal osteoporotic women 54 microdose 54 intraobserver 54 pelvic lymphadenectomy 54 placebo controlled clinical trials 54 oral allopurinol 54 hepatectomy 54 achieved PASI 54 mcg dose 54 serum creatinine levels 54 aldosterone antagonist 54 divalproex sodium 54 relapsed GBM 54 rtPA 54 BEACOPP 54 subcutaneous PRO 54 efavirenz EFV 54 NYHA Class II 54 allogeneic SCT 54 statistically significant improvement 54 antiangiogenic agent 54 μg L 54 glomerular 54 docetaxel chemotherapy 54 GIK infusion 54 perioperatively 54 ENDEAVOR II 54 tocilizumab 54 glomerular filtration 54 elevated ALT 54 serum testosterone 54 glimepiride 54 bivariate analyzes 54 Events MACE 54 clinically meaningful improvements 54 rhGH 54 #:# randomization 54 UA NSTEMI 54 relapsers 54 nodular partial response 54 ToGA 54 glufosfamide 54 baminercept 54 piperacillin tazobactam 54 micrometastasis 54 adjuvant GIST 54 urate lowering therapy 54 ertapenem 54 5-fluorouracil/leucovorin 54 Pred Forte 54 prospective observational cohort